Education
About Us
Working with TipRanks
Follow Us
Mckesson Corp. (MCK)
NYSE:MCK
MCK Analyst Ratings
Strong Buy
10 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MCK Stock 12 Month Forecast
Average Price Target
$794.27
▲(13.74% Upside)
| Highest Price Target$830.00 | Average Price Target$794.27 | Lowest Price Target$750.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$733→$763
Hold
9.26%
Upside
Reiterated
09/20/25
AI Generated ArticleAI Generated Article
Bank of America Securities
$800
Buy
14.56%
Upside
Reiterated
09/19/25
Evercore ISI
$800
Buy
14.56%
Upside
Reiterated
09/19/25
J.P. Morgan
―
Buy
―
Reiterated
09/16/25
Leerink Partners
$785
Buy
12.41%
Upside
Reiterated
09/09/25
Analysts Are Bullish on These Healthcare Stocks: McKesson (MCK), BioNTech SE (BNTX)We very much expect the overall tone of the event to be positive, building on what has been a steady above LRP growth rate from Pharma and excitement for the recent FCS/Prism deals, among other positive drivers. Our baseline assumption as noted below/in the body of note is that MCK at a minimum, has upside to its 12-14% EPS growth algorithm. This is driven by the increases in the segment LRP since 2021, which have not led to any EPS update. That creates part of the problem for the event as a whole, as two FY4Q increases to the Pharma segment AOI LRP leaves less room for upside surprise catalysts than other companies may have. Meanwhile, predicting an outcome for the Med-Surg process is hard, with clarity eventually needed to provide an upside case and unclear if clarity will come at the Investor Day.
Argus Research
$775
Buy
10.98%
Upside
Assigned
08/20/25
McKesson (MCK) Receives a Buy from Argus ResearchWe like the company’s moves to divest itself of underperforming assets to redeploy capital on faster growing, higher- margin businesses. After exiting the European distribution business, McKesson announced plans to spin-off its Medical-Surgical distribution business.
Wells Fargo
$766→$772
Hold
10.55%
Upside
Reiterated
08/13/25
Deutsche Bank
$740→$775
Buy
10.98%
Upside
Reiterated
08/07/25
Citi
$800→$820
Buy
17.43%
Upside
Reiterated
08/07/25
TD Cowen
$824→$830
Buy
18.86%
Upside
Reiterated
08/07/25
Mizuho Securities
$735→$750
Hold
7.40%
Upside
Reiterated
08/07/25
Jefferies
$800→$820
Buy
17.43%
Upside
Reiterated
07/21/25
Morgan Stanley
$770→$810
Buy
15.99%
Upside
Reiterated
07/16/25
Robert W. Baird
$796→$797
Buy
14.13%
Upside
Reiterated
06/10/25
UBS
$708→$805
Buy
15.28%
Upside
Reiterated
04/29/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$733→$763
Hold
9.26%
Upside
Reiterated
09/20/25
AI Generated ArticleAI Generated Article
Bank of America Securities
$800
Buy
14.56%
Upside
Reiterated
09/19/25
Evercore ISI
$800
Buy
14.56%
Upside
Reiterated
09/19/25
J.P. Morgan
―
Buy
―
Reiterated
09/16/25
Leerink Partners
$785
Buy
12.41%
Upside
Reiterated
09/09/25
Analysts Are Bullish on These Healthcare Stocks: McKesson (MCK), BioNTech SE (BNTX)We very much expect the overall tone of the event to be positive, building on what has been a steady above LRP growth rate from Pharma and excitement for the recent FCS/Prism deals, among other positive drivers. Our baseline assumption as noted below/in the body of note is that MCK at a minimum, has upside to its 12-14% EPS growth algorithm. This is driven by the increases in the segment LRP since 2021, which have not led to any EPS update. That creates part of the problem for the event as a whole, as two FY4Q increases to the Pharma segment AOI LRP leaves less room for upside surprise catalysts than other companies may have. Meanwhile, predicting an outcome for the Med-Surg process is hard, with clarity eventually needed to provide an upside case and unclear if clarity will come at the Investor Day.
Argus Research
$775
Buy
10.98%
Upside
Assigned
08/20/25
McKesson (MCK) Receives a Buy from Argus ResearchWe like the company’s moves to divest itself of underperforming assets to redeploy capital on faster growing, higher- margin businesses. After exiting the European distribution business, McKesson announced plans to spin-off its Medical-Surgical distribution business.
Wells Fargo
$766→$772
Hold
10.55%
Upside
Reiterated
08/13/25
Deutsche Bank
$740→$775
Buy
10.98%
Upside
Reiterated
08/07/25
Citi
$800→$820
Buy
17.43%
Upside
Reiterated
08/07/25
TD Cowen
$824→$830
Buy
18.86%
Upside
Reiterated
08/07/25
Mizuho Securities
$735→$750
Hold
7.40%
Upside
Reiterated
08/07/25
Jefferies
$800→$820
Buy
17.43%
Upside
Reiterated
07/21/25
Morgan Stanley
$770→$810
Buy
15.99%
Upside
Reiterated
07/16/25
Robert W. Baird
$796→$797
Buy
14.13%
Upside
Reiterated
06/10/25
UBS
$708→$805
Buy
15.28%
Upside
Reiterated
04/29/25
Best Analysts Covering McKesson
1 Month
xxx
Success Rate
23/34 ratings generated profit
Average Return
+2.34%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 67.65% of your transactions generating a profit, with an average return of +2.34% per trade.
3 Months
xxx
Success Rate
17/22 ratings generated profit
Average Return
+7.39%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 77.27% of your transactions generating a profit, with an average return of +7.39% per trade.
1 Year
Success Rate
29/32 ratings generated profit
Average Return
+24.50%
reiterated a buy rating 2 months ago
Copying Charles Rhyee's trades and holding each position for 1 Year would result in 90.63% of your transactions generating a profit, with an average return of +24.50% per trade.
2 Years
xxx
Success Rate
29/32 ratings generated profit
Average Return
+46.49%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.63% of your transactions generating a profit, with an average return of +46.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MCK Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
0
0
0
0
0
Buy
21
22
25
21
22
Hold
3
5
4
12
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
27
29
33
33
Each month's total comprises the sum of three months' worth of ratings.
MCK Financial Forecast
MCK Stock Forecast FAQ
What is MCK’s average 12-month price target, according to analysts?
Based on analyst ratings, Mckesson Corp.’s 12-month average price target is 794.27.
What is MCK’s upside potential, based on the analysts’ average price target?
Mckesson Corp. has 13.74% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MCK a Buy, Sell or Hold?
Mckesson Corp. has a consensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.
What is Mckesson Corp.’s price target?
The average price target for Mckesson Corp. is 794.27. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $830.00 ,the lowest forecast is $750.00. The average price target represents 13.74% Increase from the current price of $698.31.
The highest analyst price target is $830.00 ,the lowest forecast is $750.00. The average price target represents 13.74% Increase from the current price of $698.31.
What do analysts say about Mckesson Corp.?
Mckesson Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of MCK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.